Study Details

Back to Search Results

A Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02091960

Astellas Study ID

The unique identification code given by the study sponsor.

9785-CL-1121

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2013-000093-29

Follow Trial

Condition

Breast Cancer - HER2 positive, Breast Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female

Product

enzalutamide

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2014 - Dec 2023

Masking

None (Open Label)

Enrollment number

103

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US10002

Aurora, United States, 80045

Site GB44013

Manchester, United Kingdom, M20 4BX

Site US10080

Whittier, United States, 90603

Site US10042

Nashville, United States, 37203

Site IT39003

Milan, Italy, 20132

Site US10031

Houston, United States, 77030

Site BE32001

Charleroi, Belgium, 6000

Site IT39002

Milano, Italy, 20141

Site US10074

Gainsville, United States, 32605

Site US10077

Nashville, United States, 37232

Site IT39021

Udine, Italy, 33100

Site BE32003

Edegem, Belgium, 2650

Site ES34014

Pozuelo de Alarcon, Spain, 28223

Site US10021

Chicago, United States, 60611-5975

Site IT39005

Meldola, Italy, 47014

Site CA15025

Montreal, Canada, H4A 3J1

Site GB44003

Edinburgh, United Kingdom, EH4 2XU

Site ES34001

Lleida, Spain, 25198

Site US10051

Anaheim, United States, 92801

Site BE32013

Brasschaat, Belgium, 2930

Site US10076

Fort Worth, United States, 76104

Site CA15027

Sault Ste Marie, Canada, P6B 0A8

Site ES34010

Barcelona, Spain, 08035

Site US10001

Los Angeles, United States, 90033

Site US10078

St. Louis, United States, 63110

Site IT39008

Lecce, Italy, 73100

Site US10028

Los Angeles, United States, 90048

Site GB44001

Nottingham, United Kingdom, NG5 1PB

Site BE32009

Leuven, Belgium, 3000

Site US10081

Chicago, United States, 60637

Site US10079

Fort Myers, United States, 33916

Site BE32016

Bruxelles, Belgium, 1200

Site US10035

San Francisco, United States, 94115

Site ES34013

Madrid, Spain, 28050

Site CA15023

Toronto, Canada, M4N 3M5

Site US10027

Burbank, United States, 91505

Site US10070

Boston, United States, 02215

Site BE32007

Liege, Belgium, 4000

Site US10072

Cincinnati, United States, 45242

Site BE32017

Gent, Belgium, 9000

Site CA15026

Saskatoon, Canada, S7N 4H4

Site CA15001

Quebec, Canada, G1S 4L8

Site IT39001

Sondrio, Italy, 23100

Site CA15028

Regina, Canada, S4T7T1

Site CA15015

Edmonton, Canada, T6G 1Z2

Site CA15029

Montreal, Canada, H3G 1L5

Site US10082

Houston, United States, 77030

Site CA15022

Ottawa, Canada, K1H 8L6

Site US10029

Knoxville, United States, 37909

Site US10048

Pittsburgh, United States, 15213

Site GB44011

Leeds, United Kingdom, LS7 9TF

Site US10004

Indianapolis, United States, 46202

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo